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Abstract: 
Tapentadol is a single molecule able to deliver analgesia by two distinct 
mechanisms, a feature which differentiates it from many other analgesics. 
Pre-clinical data demonstrate two mechanisms of action: mu opioid 
receptor agonist activity and noradrenaline re-uptake inhibition. From 
these, one may predict that tapentadol would be applicable across a broad 
spectrum of pain from nociceptive to neuropathic. The evidence in animal 
models, suggests that NRI is a key mechanism, and may even predominate 
over opioid actions in chronic (and especially neuropathic) pain states, 
reinforcing that tapentadol is different to classical opioids and may 
therefore be an a priori choice for the treatment of neuropathic and mixed 
pain.  
The clinical studies and subsequent practice experience and surveillance 
support the concept of opioid and non-opioid mechanisms of action. The 
reduced incidence of some of the typical opioid induced side-effects, 
compared to equianalgesic doses of classical opioids supports the 
hypothesis that tapentadol analgesia is only partially mediated by opioid 
agonist mechanisms. Both the preclinical and clinical profiles appear to be 
differentiated from those of classical opioids.  
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Introduction 
Tapentadol is synthetic centrally-acting analgesic, with both opioid and non-opioid 
mechanisms of action: Mu opioid receptor agonist (MOR) and norepinephrine reuptake 
inhibition (NRI). Being an active compound and not a pro-drug, it is not reliant on enzyme 
systems , and it is also devoid of active metabolites.  
Its development, mechanisms, preclinical and clinical profiles are reviewed below, and 
compared to those of typical opioids.  Aspects are identified which differentiate tapentadol 
from typical opioids.  
 
Medicinal chemistry and pre-clinical science 
Amongst the most well-known naturally occurring therapeutic substances are alkaloids 
contained in the poppy Papaver somniferum. Of these, morphine, an alkaloid extracted from 
the poppy, is considered to be the archetypical opioid; other naturally occurring opioids 
include codeine and thebaine. 
 
Following the identification of these and other pharmacologically active alkaloids contained in 
the poppy, a vast number of similar molecules have been synthesised with minor 
modifications to the basic chemical structure. Examples of semi-synthetic opioids in clinical 
use today include diamorphine (diacetylmorphine), oxycodone and hydromorphone. In 
addition, a large number of synthetic opioid analogues with diverse chemical structures, 
including fentanyl, alfentanil, remifentanil, detropropoxyphene and methadone, have been 
synthesised and evaluated in both pre-clinical models and acute and persistent clinical pain 
conditions. 
 
In a clinical context, there are more apparent pharmacokinetic differences between opioids 
than pharmacodynamic differences.(1) Both pharmacokinetics and pharmacodynamics 
inform the choice of treatment depending on an individual patient’s type of pain and co-
morbidities. 
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     (1)         (2)         (3) 
 
Tramadol and tapentadol do not fit conveniently in the opioid classes described above. (2) 
Both are ‘atypical’ molecules in that they have pro-analgesic effects by variously modulating 
monoamine concentrations within the central nervous system, in addition to their opioid 
actions. 
 
 
 
 
 
 
            (4)          (5) 
 
Traditional methods of drug discovery rely on the synthesis and testing of a large number of 
chemical substances on cultured cells or animal models. This process can be extremely time 
consuming, resource intensive and costly. Rational drug design begins with the hypothesis 
that modulation of a known, specific biological target may have therapeutic benefit. In order 
to achieve this, one must assimilate detailed knowledge of the three dimensional structure of 
the target or other molecules that bind to the biological target of interest, thereby defining the 
pharmacophore’, this being the minimum necessary structural characteristics, a molecule 
must possess in order to bind to the target.(3) It is now clear that the different interactions 
between a drug molecule and its biological target strongly depend on the three dimensional 
spatial arrangement the drug functional groups within the target molecule.   
 
For opioids, the quantitative structural activity relationships, depend on basic 
physicochemical properties of the molecules (such as lipophilicity, hydrogen bond donor and 
acceptor properties), however these were previously estimated using a two dimensional 
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chemical representation of the molecule. The recent elucidation of the crystal structure of the 
MOR (mu-opioid receptor) may herald a new era in opioid drug discovery.(4) 
 
Understanding the analgesic benefit of multimodal mechanisms of action of the racemic 
cyclohexyl entities, such as tramadol, led to the development of tapentadol. The latter was 
the conclusion of a rational drug discovery programme to design a new class of analgesics 
that retained MOR agonism and inhibition of noradrenaline (norepinephrine) reuptake, but 
with minimal serotonergic activity. In addition, it was desired that both activities would come 
from a single molecule, and in order to minimise the interpatient variability observed with 
tramadol and codeine, activation by the hepatic cytochrome P450 enzyme system should not 
be required. That tapentadol itself is the active entity, devoid of reliance on enzymatic activity, 
is in contrast to the situation with the inactive pro-drug codeine, whose analgesic effect is 
entirely reliant on the CYP2D6 enzyme for conversion to morphine. CYP2D6 enzyme activity 
depends on the genotype, ranging from no analgesic benefit with complete absence, to 
elevated expression in ‘fast metabolisers’, leading to increased side effects and potentially 
serious complications. The latter led to codeine’s absolute contraindication in paediatric 
practice. 
 
Tapentadol: analgesic mechanisms 
Studies in animals, using a number of behavioural, pharmacological, neurochemical and 
neural measures have validated the MOR and NRI components of tapentadol’s mechanism 
of action.(2) 
Central hyperexcitability plays important roles in determining the level of pain perceived. 
Rightly, much emphasis has been put on spinal cord mechanisms in central excitability, but it 
is now accepted that the spinal cord can also be regulated by descending pathways from the 
brain, both excitatory and inhibitory. These pathways act through monoamine systems, 
mediated by noradrenaline and 5-HT, with the former being inhibitory. Not only do these 
descending pathways interact with opioid controls at spinal and brainstem levels, but they are 
the rationale for the use of TCAs and SNRIs.(5)  Thus the drug tapentadol is of interest in 
terms of combining two inhibitory actions in one molecule: mu opioid receptor (MOR) 
agonism and noradrenaline re-uptake inhibition (NRI). Data with this drug suggests this 
combination seems to produce a synergistic anti-nociceptive action in animal models of 
tissue and nerve damage pains.(6) The drug is effective in models of acute pain, 
osteoarthritic, neuropathic and the mixed pain state of cancer-induced bone pain and in all 
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cases both the MOR and NRI contributions can be observed.  
Interestingly, with persistent neuropathic pain models the NRI component becomes 
predominant, as demonstrated by selective blockade of NRI or opioid based actions using 
yohimbine or naloxone, respectively.(7)  
That tapentadol is differentiated from classical, single mechanism pure opioids, is further 
demonstrated most convincingly in ‘knock-out’ animals with a genetic deletion of the MOR, 
with the drug retaining efficacy in both acute and persistent neuropathic pain models.(8). 
Thus, the ability of tapentadol to retain activity in the absence of MOR activity means it is not 
sufficient to label it just ‘an opioid’ without acknowledging the major noradrenergic component 
to its actions. Recently, Diffuse Noxious Inhibitory Controls (DNIC), an endogenous inhibitory 
system mediated by descending controls has been shown to be noradrenergic and is lost 
after nerve injury. DNIC are restored by tapentadol (9) corroborating the concept that the 
mechanism of restoring NA modulation can alleviate pain. (10) 
Together, the lack of potentially meaningful 5-HT effect and the relatively weak MOR affinity 
may explain the better tolerability than with a pure opioid at equianalgesic doses. Typical 
opioid effects on gastrointestinal motility and vomiting are reduced with tapentadol compared 
to classical opioids in animal models. By contrast, sweating, potentially attributable to NRI, is 
more common in humans with tapentadol than pure opioids.  
Preclinical studies suggest that this combined and synergistic MOR and NRI activity might 
translate to an ability to be effective in a wide range of painful conditions with reduced opioid 
related side effects. Thus, tapentadol is effective in models of nerve injury and inflammation 
as well as predictably, in cancer induced bone pain, a mixed pain state with elements of both 
nociceptive and neuropathic pain.  
 
Clinical aspects 
Tapentadol has been investigated in a many acute and chronic pain conditions including 
post-surgical, musculoskeletal and neuropathic pains.   
In a pooled analysis of three randomised controlled trials in chronic pain, nearly 3000 patients 
with predominantly severe osteoarthritis (OA) pain or low back pain, prolonged release 
tapentadol was compared to placebo and an active comparator, oxycodone CR (Controlled 
Release).(11) Both of the active comparators were significantly superior to placebo, and 
tapentadol demonstrated analgesic efficacy which was ‘non-inferior’ to oxycodone CR. 
Recently, a further planned analysis of this data set has shown superiority for tapentadol over 
oxycodone.(12) Furthermore, patients taking tapentadol PR experienced improved tolerability 
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with fewer side effects particularly during the titration phase compared to patients taking 
oxycodone CR. In contrast, patients taking oxycodone CR exhibited higher rates of early 
treatment discontinuation, attributed to gastrointestinal side effects classically associated with 
opioids (constipation, nausea and vomiting). The tapentadol group patients had a similar 
discontinuation rate (36.8 %) to patients taking placebo (35.0 %), both of which were 
markedly lower than for patients taking oxycodone (55.4 %).(11) This improved tolerability 
profile would seem to be compatible with the preclinical study evidence that tapentadol’s 
efficacy is only partially derived from opioid mediated mechanisms, and hence has a clinical 
profile different to a pure mu opioid agonist.  Tapentadol’s non-opioid NRI mechanism of 
action may contribute to its demonstrated analgesic efficacy in patients with painful diabetic 
neuropathy.(13) 
 
The concept of ‘mixed pain’ (for example in low back pain) is increasingly recognised and 
accepted and may comprise inflammatory, musculoskeletal and neuropathic pain 
mechanisms, for which a multimodal analgesic approach would be appropriate.  
Tapentadol was shown to be effective in an open label trial of patients with chronic low back 
pain, in which the ‘pain DETECT’ neuropathic pain screening tool was used to characterise 
each patient’s pain.(14) Patients with a detectable neuropathic pain component required 
lower doses of tapentadol (than patients without neuropathic pain features), which in turn was 
associated with a reduction in opioid-related side-effects, again potentially also attributable to 
the NRI mechanism and relatively less opioid activity.(15) Tapentadol’s NRI based 
mechanism may contribute to enhanced management of neuropathic pain and is also 
supported by a recent randomised, controlled, open-label 12 week study of patients with 
severe chronic low back pain with a neuropathic component. Change from baseline in pain 
intensity with tapentadol PR was found to be superior to oxycodone/naloxone PR (P=0.003).   
 
Androgen deficiency (OPiAd) is a recognised effect of long-term opioid (MOR) agonists use 
in males, which may result in erectile dysfunction, decreased sperm counts, small testes, and 
loss of body hair. That tapentadol analgesia may only be partially mediated via the MOR, 
provided the rationale for a twelve week study of serum testosterone levels in male patients 
(≤64 years of age), conducted in a subset of the patients (described above) with severe low 
back pain with a neuropathic pain component, randomised to receive twice-daily tapentadol 
PR or oxycodone/naloxone PR.(15,16) The baseline testosterone levels were normal in all 
subjects, but by the final evaluation at week 12 (or early study termination), 45.5% (5/11) of 
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the oxycodone/naloxone PR groups had low (below normal) testosterone levels compared to 
only 10.5% (2/19) of the patients receiving tapentadol PR. There was a significant decrease 
from baseline to final evaluation in least-squares mean (SD) testosterone levels in the 
oxycodone/naloxone PR group (–4.23 [1.232] nMol/L; P = 0.004), but not in the tapentadol 
PR group (–1.50 [0.946] nMol/L; P = 0.134) (16)  These results further support the premise 
that tapentadol may exert a relatively smaller magnitude of opioid mediated effect.  
 
Opioid loads and issues 
In routine clinical practice, it is common to switch or rotate between different opioids. In order 
to do this safely and successfully it is essential to have knowledge of the relative potency or 
equivalences of the opioids being used, and a range of reference sources and decision tools 
are available to support the conversion. Most clinical studies have suggested that tapentadol 
50 mg has a similar efficacy to oxycodone 10 mg.(17,18) However, for drugs such as 
tramadol and tapentadol that have other mechanisms that contribute to their analgesic effect, 
it is essential to consider analgesic quivalence rather than opioid equivalence. Analgesic 
equivalence with tapentadol may be achieved with lower opioid receptor activity than a drug 
that only acts on opioid receptors, which may have implications for tolerability and switching. 
 
Evidence of the lesser contribution of opioid action in tapentadol-mediated analgesia is also 
supported by the observation that switching a patient from a high dose of conventional opioid 
to an equianalgesic dose of tapentadol may lead to features of acute opioid withdrawal.(19)   
 
A further benefit of these mixed mechanism agents appears to be reflected in their reduced 
potential for abuse and diversion compared to other opioids. The Researched Abuse, 
Diversion and Addiction-Related Surveillance (‘RADARS’) system during the first 24 months 
following the initial release and marketing of tapentadol IR in the USA, found rates of abuse 
and diversion were much lower than for oxycodone or hydrocodone.(20) Similarly, the rate of 
non-medical use of tapentadol (Immediate Release) by college students was lower than other 
opioids and common drugs of abuse.(21)  
 
Summary 
Tapentadol is a single molecule able to deliver analgesia by two distinct mechanisms, a 
feature which differentiates it from many other analgesics. Pre-clinical data demonstrate the 
MOR and NRI mechanisms and predict that tapentadol would be applicable across a broad 
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spectrum of pain from nociceptive to neuropathic. The evidence in animal models, suggests 
that NRI is a key mechanism, and may even predominate over opioid actions in chronic (and 
especially neuropathic) pain states, reinforcing that tapentadol is different to classical opioids 
and may therefore be an a priori choice for the treatment of neuropathic and mixed pain.  
The clinical studies and subsequent practice experience and surveillance support the 
concept of opioid and non-opioid mechanisms of action. The reduced incidence of some of 
the typical opioid induced side-effects, compared to equianalgesic doses of classical opioids 
supports the hypothesis that tapentadol analgesia is only partially mediated by opioid agonist 
mechanisms. Both the preclinical and clinical profiles appear to be differentiated from those 
of classical opioids.  
 
 
 
 
 
References 
 
(1) Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, 
Dahan A. Differences between opioids: pharmacological, experimental, clinical and 
economical perspectives. Br J Clin Pharmacol 2013; 75(1):60-78. 
 
(2) Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, 
Hertrampf T, Kogel B, Schiene K, Strassburger W, Terlinden R, Tzschentke TM. Mechanistic 
and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012; 
13(10):1437-1449. 
 
(3) Hahn M. Three-Dimensional Shape-Based Searching of Conformationally Flexible 
Compounds. J Chem Inf Comput Sci 1997; 37:80-86. 
 
(4) Manglik A1, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, 
Weis WI, Kobilka BK, Granier S Crystal structure of the µ-opioid receptor bound to a 
morphinan antagonist. Nature. 2012. 485(7398):321-6 
 
(5) Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to 
Page 7 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 8 
monoaminergic pain modulation. Neurotherapeutics 2009; 6(4):703-712. 
 
(6) Christoph T, Schroder W, Tallarida RJ, De VJ, Tzschentke TM. Spinal-supraspinal and 
intrinsic mu-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of 
tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 2013; 347(3):794-
801 
 
(7) Tzschentke TM, Christoph T, Schröder W, et al. Tapentadol: with two mechanisms of 
action in one molecule effective against nociceptive and neuropathic pain : Preclinical 
overview. Schmerz. 2011;25:19-25 
 
(8) Kogel B, De VJ, Tzschentke TM, Christoph T. The antinociceptive and antihyperalgesic 
effect of tapentadol is partially retained in OPRM1 (mu-opioid receptor) knockout mice. 
Neurosci Lett 2011; 491(2):104-107. 
 
(9) Bannister K, Patel R, Goncalves L, Townson L, Dickenson AH.  DNIC and nerve injury: 
restoring an imbalance between descending monoamine inhibitions and facilitations. Pain. 
2015;156(9):1803-11    
 
(10) Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates 
descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J 
Anaesth. 2014;113(1):148-56    
 
(11) Lange B, Kuperwasser B, Okamoto A, Steup A, Haufel T, Ashworth J, Etropolski M. 
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low 
back pain. Adv Ther 2010; 27(6):381-399. 
(12) Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I Practical 
considerations for the use of tapentadol prolonged release for the management of severe 
chronic pain. Clin Ther  2015; 37: 94-113 
 
(13) Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb 
C. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral 
neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 
Page 8 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9 
2011;27(1):151-62 
 
(14) Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening 
questionnaire to identify neuropathic components in patients with back pain. Curr Med Res 
Opin 2006; 22(10):1911-20. 
 
(15) Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Müller M, Falke D, Steigerwald I. 
Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone 
PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A 
Randomized, Controlled, Open-Label, Phase 3b/4 Study. Pain Practice 2015. Published 
online 
 
(16) Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) 
Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain 
with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial 
Baron R, Jansen J-P, Binder A, Pombo-Suarez M, Kennes L, Muller M, Falke D, Steigerwald 
I. Pain Pract. 2015. Published online 
 
(17) Daniels SE, Golf M. Clinical efficacy and safety of tapentadol immediate 
release in the postoperative setting. J Am Podiatr Med Assoc. 2012;102(2):139-48   
 
(18) Stegmann JU, et al  The efficacy and tolerability of multiple-dose tapentadol immediate 
release for the relief of acute pain following orthopedic (bunionectomy) surgery . Curr Med 
Res Opin. 2008 Nov;24(11):3185-96 
 
(19) Mercadante S, Porzio G and Gebbia V. New Opioids. Journal of Clinical Oncology. 2014; 
32(16):1671-6 
 
(20) Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of 
the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag 2012; 
8(6):395-402 
 
(21)  Dart RC, Adams E, Bucher Bartelson B, Baker G, Pitner J, Vorsanger G. Trends in the 
Page 9 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10
Non-Medical Use of Tapentadol Immediate Release by College Students. Poster presented 
at the American Academy of Pain Medicine (AAPM) February 23-26. 2012 
Page 10 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Declaration 
This article was conceived at an expert advisory board of pain experts, 
arranged by and paid for by Grünenthal Ltd, with funding of the subsequent 
writing process. However, the manuscript was produced solely by the four 
authors, devoid of any editorial input or influence. Grünenthal Ltd has only 
checked the article for correctness and has not exercised any editorial rights. 
 
Acknowledgements: 
Thanks are expressed to the following panel members (additional to the 
authors): 
Beverly Collett 
Martin Johnson 
Victor Mendis 
Val Conway 
Andrew Nicalaou 
 
 
Page 11 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 1 
 
 
 
 
 
 
     (1)         (2)         (3) 
 
 
 
 
 
 
 
            (4)          (5) 
 
   (4)      (5) 
Page 12 of 12
https://mc.manuscriptcentral.com/bjpain
British Journal of Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
